Retina
Chapters
-
1. Do intravitreal corticosteroids have any systemic effects?
00:00:33 -
2. Balancing the therapeutic benefits of OZURDEX® (dexamethasone) and the risk of accelerated cataract progression
00:02:24 -
3. Discussing the risk of cataract progression with your pre-presbyopic patients
00:05:18 -
4. When to give OZURDEX® (dexamethasone) if patient has upcoming cataract surgery?
00:10:39 -
5. Counselling the phakic OZURDEX® (dexamethasone) patient
00:13:36 -
6. References
00:16:37
Chapters
-
1. Introduction
00:00:00 -
2. Potential IOP spikes following OZURDEX® (dexamethasone) injection
00:00:45 -
3. What is the recommended schedule for monitoring IOP after an OZURDEX® (dexamethasone) injection?
00:02:58 -
4. How to monitor glaucoma risk in OZURDEX® (dexamethasone) patients?
00:04:50 -
5. What to do if there is an IOP spike following an OZURDEX® (dexamethasone) injection?
00:06:50 -
6. References
00:11:28
Chapters
-
1. Introduction
00:00:00 -
2. Defining treatment failure in DMO
00:01:27 -
3. What to do when anti-VEGF treatment fails in a DMO patient
00:03:06 -
4. Defining treatment failure in RVO patients
00:06:37 -
5. The importance of early detection of treatment failure in DMO and RVO patients
00:07:56 -
6. Thinking ahead and discussing treatment options in advance
00:09:30 -
7. References
00:10:50
Chapters
-
1. Introduction
00:00:00 -
2. Key challenges facing RVO patients
00:00:37 -
3. The real-world efficacy gap of anti-VEGF therapy in RVO treatment
00:02:18 -
4. Alternative treatment options for RVO patients with suboptimal or no response to anti-VEGF therapy
00:06:20 -
5. Identifying RVO patients suitable for OZURDEX® (dexamethasone) treatment
00:07:55 -
6. When to start thinking about switching from anti-VEGF to OZURDEX® (dexamethasone)?
00:08:51 -
7. How to define RVO treatment goals?
00:11:41 -
8. Differences between managing RVO compared to DMO
00:13:08 -
9. References
00:16:33
Chapters
-
1. Disclosure
00:00:00 -
2. Introduction
00:00:20 -
3. Is macular oedema an angiogenic or inflammatory disease?
00:00:35 -
4. What are the associations between inflammation and retinal vein occlusion?
00:02:39 -
5. What inflammatory mediators are upregulated in retinal vein occlusion?
00:04:26 -
6. How do you address the different components when treating macular oedema?
00:06:50
DMO & RVO Insights Series - Being prepared for when your DMO patient needs a Plan B
Presented by Dr Rohan Gupta (Glaucoma & Cataract Surgeon) and Dr Hemal Mehta (Retinal Specialist), this video is about optimal treatment and management of DMO patients and being prepared for when those patients need a Plan B.
Chapters
-
1. Introduction
00:00:00 -
2. Is anti-VEGF suitable for all DMO patients?
00:00:35 -
3. Does anti-VEGF work for all DMO patients?
00:03:12 -
4. The real-world efficacy gap in DMO patients
00:05:17 -
5. Alternatives to anti-VEGF
00:07:19 -
6. When to consider switching from anti-VEGFs?
00:10:03 -
7. Suitable OZURDEX® DMO patients
00:11:17 -
8. Are there Australian guidelines?
00:12:45 -
9. References
00:14:53
PBS Information
OZURDEX: Authority required for the treatment of DMO, RVO and non-infectious posterior segment uveitis. Refer to PBS Schedule for full authority information.
Please review the full Product Information (PI) before prescribing, available below.
AU-OPHTHG-230037. June 2024